A study identified a novel APOE4-specific receptor LilrB3. A butterfly-like Cryo-EM structure of the complex reveals the details of how the immune “checkpoint” receptor LilrB3 recognizes APOE4.

APOE3 is thought to confer a neutral risk of the disease. APOE4, on the other hand, is bad news. It has long been recognized that people with at least one copy of the APOE4 gene have an elevated ...

For more than 30 years, Alzheimer’s researchers have thought of APOE4 as a major genetic risk factor for most cases of the devastating neurologic disease. But a new study published on Monday ...

NEW YORK, April 21 (Reuters) - APOE4 is the strongest risk factor for late-onset Alzheimer's, the most common form of the disease that develops after the age of 65, according to the National ...

and Lynn Scaduto Mind Institute at Miami Jewish Health in Florida. But not everyone with two copies of APOE4 had other clinical symptoms, which usually are the trigger for an Alzheimer’s ...

In a recent study published in the journal Scientific Reports, researchers compare the impact of apolipoprotein E ε4 (APOE4) levels on mortality risk. APOE4 is a well-known genetic risk factor ...

In this new study, the research team has found evidence suggesting that AD due to homozygous APOE4 genes should be classified as a third general type of the disease, rather than as a risk factor.

Non-APOE4 carriers do not benefit from treatment with lecanemab. Lecanemab reduces the rate of progression of APOE4 carriers closer to that of non-carriers in mild Alzheimer's disease. While rare ...

People with two copies of the gene variant APOE4 are almost certain to get Alzheimer’s, say researchers, who proposed a framework under which such patients could be diagnosed years before symptoms.

The study, published today in Nature Medicine, also concludes that those individuals homozygous for APOE4 also develop the disease earlier than those with other variants of the APOE gene.

Topline results were announced from a phase 3 trial evaluating valiltramiprosate (ALZ-801) in apolipoprotein ε4 allele (APOE4) carriers with early Alzheimer disease (AD). Valiltramiprosate is an ...